Share Issue/Capital Change • Jul 4, 2022
Share Issue/Capital Change
Open in ViewerOpens in native device viewer
Public limited company with a capital of € 27 876 782.75 Registered office: 49 boulevard du Général Martial Valin - 75015 Paris 410 910 095 R.C.S. on the Paris Trade and Companies Register
Under the liquidity contract entered into between ONXEO and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30 th 2021:
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.
Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
platON is Onxeo's proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company's product pipeline.
AsiDNA, the first compound from platON, is a highly differentiated, clinical-stage first-in-class candidate in the field of DNA damage response (DDR) applied to oncology. Its decoy and agonist mechanism acting upstream of multiple DDR pathways results in distinctive antitumor properties, including the ability to prevent or abrogate tumor resistance to targeted therapies such as PARP inhibitors and strong synergy with tumor DNA-damaging agents such as radio-chemotherapy. AsiDNA is currently being studied in Europe in combination with other treatment modalities in difficult-to-treat solid tumors.
OX400 is a series of new drug candidates from platON, designed to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. The lead OX400 candidate is currently being optimized and is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.
This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the risk factors described in the most recent Company's registration document or in any other periodic financial report and in any other press release, which are available free of charge on the websites of the Company Group (www.onxeo.com) and/or the AMF (www.amf-france.org).
| Onxeo | Media Relations | Investor Relations / Strategic Communication |
|---|---|---|
| Investor Relations | Arthur Rouillé | Dušan Orešanský / Emmanuel Huynh |
| [email protected] | NewCap | NewCap |
| [email protected] | [email protected] | |
| +33 1 45 58 76 00 | +33 1 44 71 94 98 | +33 1 44 71 94 92 |
Kapital Partner www.kapitalpartner.dk [email protected] +45 89 88 78 46
| Buy Side | Sell Side | |||||
|---|---|---|---|---|---|---|
| Number of executions |
Number of shares |
Traded volume in EUR |
Number of executions |
Number of shares |
Traded volume in EUR |
|
| Total | 255 | 269,935 | 99,624.74 | 222 | 251,351 | 96,727.03 |
| 03/01/2022 | - | - | - | 2 | 10,000 | 4,400.00 |
| 04/01/2022 | 3 | 5,000 | 2,200.00 | 1 | 5,000 | 2,250.00 |
| 05/01/2022 | 2 | 5,000 | 2,150.00 | - | - | - |
| 06/01/2022 | 2 | 5,000 | 2,100.00 | - | - | - |
| 07/01/2022 | - | - | - | 14 | 7,267 | 3,124.81 |
| 10/01/2022 | 2 | 4,193 | 1,761.06 | - | - | - |
| 11/01/2022 | 6 | 5,807 | 2,497.01 | 3 | 12,733 | 5,602.52 |
| 12/01/2022 | 1 | 4,645 | 1,997.35 | - | - | - |
| 13/01/2022 | 3 | 7,786 | 3,347.98 | 1 | 5,000 | 2,200.00 |
| 17/01/2022 | 1 | 2,569 | 1,078.98 | - | - | - |
| 20/01/2022 | 1 | 5,000 | 2,050.00 | - | - | - |
| 24/01/2022 | 3 | 5,000 | 2,000.00 | 1 | 1 | 0.42 |
| 25/01/2022 | - | - | - | 2 | 5,000 | 2,050.00 |
| 28/01/2022 | 2 | 1,443 | 577.20 | - | - | - |
| 31/01/2022 | 1 | 1 | 0.40 | 2 | 2,894 | 1,215.48 |
| 01/02/2022 | 1 | 3,556 | 1,422.40 | - | - | - |
| 03/02/2022 | - | - | - | 1 | 2,133 | 874.53 |
| 09/02/2022 | 3 | 625 | 243.75 | - | - | - |
| 10/02/2022 | 6 | 4,376 | 1,706.64 | 1 | 1 | 0.40 |
| 11/02/2022 | 1 | 1 | 0.40 | 1 | 1 | 0.40 |
| 16/02/2022 | 1 | 1 | 0.40 | 1 | 1 | 0.40 |
| 21/02/2022 | 4 | 10,000 | 3,800.00 | 1 | 1 | 0.38 |
| 22/02/2022 | 4 | 5,000 | 1,800.00 | 5 | 1,529 | 565.73 |
| 23/02/2022 | - | - | - | 10 | 3,471 | 1,284.27 |
| 24/02/2022 | 13 | 15,235 | 5,332.25 | - | - | - |
| 25/02/2022 | 2 | 4,765 | 1,572.45 | 9 | 6,071 | 2,064.14 |
| 28/02/2022 | - | - | - | 7 | 8,929 | 3,125.15 |
| 01/03/2022 | 3 | 2,410 | 819.40 | 8 | 25,000 | 9,250.00 |
| 02/03/2022 | 4 | 4,362 | 1,570.32 | 2 | 301 | 114.38 |
| 03/03/2022 | - | - | - | 1 | 1 | 0.38 |
| 04/03/2022 | 10 | 18,475 | 6,281.50 | - | - | - |
| 07/03/2022 | 13 | 15,000 | 4,800.00 | - | - | - |
| 08/03/2022 | - | - | - | 2 | 5,000 | 1,650.00 |
| 09/03/2022 | - | - | - | 7 | 18,860 | 6,789.60 |
| 11/03/2022 | 1 | 5,000 | 1,700.00 | - | - | - |
| 15/03/2022 | 1 | 1 | 0.35 | 2 | 2,001 | 720.36 |
| 16/03/2022 | 1 | 1 | 0.35 | 1 | 2,000 | 740.00 |
|---|---|---|---|---|---|---|
| 17/03/2022 | 2 | 2,001 | 720.36 | 1 | 1 | 0.36 |
| 18/03/2022 | 4 | 2,122 | 742.70 | 2 | 2,000 | 740.00 |
| 22/03/2022 | - | - | - | 4 | 2,000 | 740.00 |
| 23/03/2022 | 3 | 2,001 | 720.36 | 1 | 1 | 0.37 |
| 24/03/2022 | 7 | 2,001 | 720.36 | 5 | 2,001 | 720.36 |
| 28/03/2022 | 2 | 555 | 194.25 | 3 | 2,000 | 720.00 |
| 29/03/2022 | 4 | 2,000 | 720.00 | 1 | 100 | 37.00 |
| 30/03/2022 | 2 | 180 | 63.00 | - | - | - |
| 31/03/2022 | 1 | 1,265 | 442.75 | 5 | 2,001 | 740.37 |
| 01/04/2022 | - | - | - | 20 | 29,899 | 11,959.60 |
| 04/04/2022 | 2 | 930 | 372.00 | 2 | 4,000 | 1,720.00 |
| 05/04/2022 | - | - | - | 4 | 4,000 | 1,720.00 |
| 06/04/2022 | 3 | 4,000 | 1,720.00 | 6 | 8,000 | 3,440.00 |
| 07/04/2022 | 3 | 4,000 | 1,640.00 | 4 | 3,842 | 1,652.06 |
| 08/04/2022 | 6 | 8,000 | 3,360.00 | - | - | - |
| 11/04/2022 | - | - | - | 1 | 2,000 | 840.00 |
| 12/04/2022 | 1 | 1 | 0.41 | 1 | 1 | 0.41 |
| 13/04/2022 | 4 | 6,615 | 2,579.85 | 3 | 2,000 | 800.00 |
| 14/04/2022 | 4 | 6,000 | 2,280.00 | - | - | - |
| 19/04/2022 | 1 | 2,000 | 760.00 | 1 | 2,000 | 780.00 |
| 20/04/2022 | 3 | 2,000 | 760.00 | 3 | 6,000 | 2,340.00 |
| 22/04/2022 | 1 | 1 | 0.39 | 4 | 2,838 | 1,135.20 |
| 25/04/2022 | 3 | 2,000 | 780.00 | - | - | - |
| 26/04/2022 | 2 | 127 | 49.53 | 2 | 1,164 | 465.60 |
| 27/04/2022 | 3 | 3,875 | 1,511.25 | 1 | 1 | 0.39 |
| 28/04/2022 | 5 | 2,001 | 760.38 | 1 | 1 | 0.38 |
| 29/04/2022 | 2 | 1,881 | 695.97 | - | - | - |
| 02/05/2022 | 3 | 2,120 | 784.40 | 2 | 401 | 152.38 |
| 03/05/2022 | - | - | - | 2 | 445 | 169.10 |
| 04/05/2022 | 2 | 2,001 | 720.36 | 1 | 1 | 0.38 |
| 05/05/2022 | 7 | 5,999 | 2,099.65 | - | - | - |
| 06/05/2022 | 2 | 780 | 273.00 | 4 | 4,000 | 1,440.00 |
| 09/05/2022 | 3 | 3,220 | 1,127.00 | - | - | - |
| 10/05/2022 | 1 | 800 | 280.00 | 2 | 4,000 | 1,440.00 |
| 11/05/2022 | - | - | - | 5 | 4,000 | 1,440.00 |
| 12/05/2022 | 3 | 3,200 | 1,120.00 | - | - | - |
| 16/05/2022 | 2 | 4,000 | 1,360.00 | - | - | - |
| 17/05/2022 | - | - | - | 2 | 2,000 | 700.00 |
| 18/05/2022 | 3 | 4,000 | 1,360.00 | - | - | - |
| 23/05/2022 | - | - | - | 1 | 2,000 | 700.00 |
| 24/05/2022 | 1 | 1 | 0.34 | 2 | 2,001 | 700.35 |
| 25/05/2022 | 6 | 2,000 | 680.00 | 1 | 1,000 | 350.00 |
| 27/05/2022 | 1 | 1 | 0.34 | 1 | 1 | 0.34 |
|---|---|---|---|---|---|---|
| 30/05/2022 | 1 | 35 | 11.90 | 1 | 2,000 | 700.00 |
| 31/05/2022 | 1 | 1 | 0.35 | 1 | 1 | 0.35 |
| 01/06/2022 | 6 | 3,965 | 1,387.75 | 1 | 1 | 0.36 |
| 02/06/2022 | 2 | 81 | 28.35 | 5 | 2,000 | 720.00 |
| 03/06/2022 | 1 | 523 | 183.05 | - | - | - |
| 06/06/2022 | 1 | 1 | 0.35 | - | - | - |
| 07/06/2022 | 1 | 1 | 0.36 | 5 | 2,029 | 730.44 |
| 08/06/2022 | 2 | 3,396 | 1,188.60 | - | - | - |
| 09/06/2022 | 1 | 2,000 | 680.00 | - | - | - |
| 10/06/2022 | - | - | - | 1 | 1 | 0.35 |
| 13/06/2022 | 3 | 2,000 | 680.00 | 1 | 1,999 | 699.65 |
| 14/06/2022 | 6 | 4,127 | 1,444.45 | - | - | - |
| 15/06/2022 | 8 | 11,873 | 3,918.09 | 2 | 3,767 | 1,243.11 |
| 16/06/2022 | 3 | 3,199 | 1,023.68 | 2 | 3,500 | 1,155.00 |
| 17/06/2022 | 1 | 801 | 248.31 | 4 | 1,157 | 381.81 |
| 20/06/2022 | 1 | 120 | 38.40 | 4 | 4,000 | 1,320.00 |
| 21/06/2022 | 2 | 3,880 | 1,241.60 | - | - | - |
| 22/06/2022 | 1 | 1 | 0.33 | 1 | 1 | 0.33 |
| 23/06/2022 | - | - | - | 4 | 6,000 | 2,040.00 |
| 24/06/2022 | 3 | 2,251 | 742.83 | 4 | 3,272 | 1,112.48 |
| 27/06/2022 | 3 | 1,284 | 436.56 | 3 | 2,729 | 955.15 |
| 28/06/2022 | 6 | 2,716 | 923.44 | - | - | - |
| 29/06/2022 | 3 | 753 | 248.49 | - | - | - |
| 30/06/2022 | 2 | 2,997 | 989.01 | - | - | - |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.